Free Trial
→ Musk's warning signal: Prepare before the cascade begins (From InvestorPlace) (Ad)
NASDAQ:EVAX

Evaxion Biotech A/S Q3 2023 Earnings Report

Evaxion Biotech A/S logo
$1.53 +0.03 (+2.00%)
As of 04/30/2025 03:59 PM Eastern
Earnings HistoryForecast

Evaxion Biotech A/S EPS Results

Actual EPS
-$10.50
Consensus EPS
-$9.50
Beat/Miss
Missed by -$1.00
One Year Ago EPS
N/A

Evaxion Biotech A/S Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evaxion Biotech A/S Announcement Details

Quarter
Q3 2023
Date
12/19/2023
Time
Q3 2023 Earnings Release
Conference Call Date
Tuesday, December 19, 2023
Conference Call Time
2:00AM ET

Upcoming Earnings

Evaxion Biotech A/S' Q1 2025 earnings is scheduled for Tuesday, May 27, 2025, with a conference call scheduled at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q1 2025 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

Evaxion Biotech A/S's Q3 2023 Press ReleasePress Release
(8-K)

Evaxion Biotech A/S Earnings Headlines

Evaxion Reports Positive Data For Vaccine Candidate EVX-01
April 30 at 7:17 PM | nasdaq.com
Evaxion Biotech Reports 80% Tumor-Specific Immune Response from EVX-01 Cancer Vaccine in Phase 2 Trial
April 30 at 7:17 PM | nasdaq.com
The Worst Year in American Financial History?
Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behind all the chaos you've seen play out in the global economy in 2025. This curse has nothing to do with astrology or anything metaphorical. In fact, it's studied at the highest levels of finance and academia ... and VP Vance even questioned Jerome Powell about it. It's a wild money story you could soon hear everywhere. Only one investigative journalist is telling the story here.
May 1, 2025 | Stansberry Research (Ad)
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting
April 28 at 8:00 AM | globenewswire.com
Evaxion Biotech: Evaxion to present at World Vaccine Congress
April 10, 2025 | finanznachrichten.de
Evaxion to present at World Vaccine Congress
April 10, 2025 | globenewswire.com
See More Evaxion Biotech A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evaxion Biotech A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evaxion Biotech A/S and other key companies, straight to your email.

About Evaxion Biotech A/S

Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

View Evaxion Biotech A/S Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles